Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)

China flag China · Delayed Price · Currency is CNY
6.17
+0.26 (4.40%)
At close: Mar 10, 2026
7.30%
Market Cap 4.05B
Revenue (ttm) 141.77M
Net Income (ttm) -241.61M
Shares Out 656.23M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,071,200
Average Volume 8,174,685
Open 5.95
Previous Close 5.91
Day's Range 5.95 - 6.19
52-Week Range 4.67 - 10.31
Beta 0.74
RSI 50.15
Earnings Date Mar 28, 2026

About SHA:688373

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment... [Read more]

Sector Healthcare
Founded 2007
Employees 177
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688373
Full Company Profile

Financial Performance

In 2025, SHA:688373's revenue was 141.77 million, an increase of 8.83% compared to the previous year's 130.27 million. Losses were -241.61 million, -45.18% less than in 2024.

Financial Statements

News

There is no news available yet.